The ATM offering provides a modest cash runway extension for a company with limited resources and a going concern risk. Monitor the pace of ATM sales via subsequent 424B5 filings and the next 6-K for quarterly results to assess cash burn and any progress on Nasdaq compliance. The stock is under severe distress; any positive operational catalyst would need to be material to offset the dilutive overhang.
Price Chart
Executive Summary
Evogene Ltd. filed a 6-K on June 11, 2026, disclosing entry into a Sales Agreement with A.G.P./Alliance Global Partners for an at-the-market (ATM) offering of ordinary shares up to $2,926,500. This filing is the companion disclosure to the 424B5 filed the same day, which was previously rated bearish (impact 7/10) due to the company's limited cash ($8.5M as of March 31, 2026), Nasdaq minimum bid price non-compliance, and going concern audit matter. The ATM offering provides modest cash runway extension but dilutes existing shareholders by up to ~40%.
Key Facts
- Evogene entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners on June 11, 2026.
- The ATM offering is for up to $2,926,500 of ordinary shares.
- The company pays a 3.0% cash commission on gross proceeds from sales.
- The 424B5 filed the same day was previously analyzed as bearish (impact 7/10) citing limited cash ($8.5M as of March 31, 2026), Nasdaq non-compliance, and going concern audit matter.
- The 20-F annual report filed March 26, 2026 provides context on the company's financial position and going concern risk.
Financial Impact
Up to $2,926,500 in gross proceeds from ATM sales, net of 3.0% agent commission. Dilution of up to ~40% of shares outstanding based on prior analysis.
Risk Factors
- Dilution from ATM sales could further pressure the stock price.
- Nasdaq delisting risk if the minimum bid price deficiency is not cured.
- Going concern risk as highlighted in the 20-F audit opinion.
- Limited cash runway may force additional dilutive financing or restructuring.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003169 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-003169 |
| Document: zk2635529.htm | 0001178913-26-003169 |
| Document: 0001178913-26-003169-index-headers.html | 0001178913-26-003169 |
| Document: 0001178913-26-003169-index.html | 0001178913-26-003169 |
| Document: 0001178913-26-003169.txt | 0001178913-26-003169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $0.3641 | awaiting T+60 | — | $0.3638 (−0.08%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4106 | awaiting T+60 | — | $0.3638 (−11.40%) |
Oct 6, 2026 21d ago | 6-K | $0.4106 | awaiting T+60 | — | $0.3638 (−11.40%) |
Sep 30, 2026 27d ago | 6-K | $0.4000 | awaiting T+60 | — | $0.3638 (+9.05%) |
Sep 30, 2026 27d ago | EFFECT | $0.4000 | awaiting T+60 | — | $0.3638 (+9.05%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | — | $0.3638 (−32.37%) |
Aug 18, 2026 10w ago | 6-K | $0.5826 | awaiting T+60 | — | $0.3638 (−37.56%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | — | $0.3638 (−39.45%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 $0.3466 | ▼ −35.81% | ▼ −37.60% | $0.3638 (−32.63%) |
Jun 16, 2026 19w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3638 (−35.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers